Lapatinib - CISMeF

Preferred Label : Lapatinib;

NCIt related terms : GW572016; GW 2016;

NCIt definition : A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.;

Alternative definition : NCI-GLOSS: A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.;

UNII : 0VUA21238F;

InChIKey : BCFGMOOMADDAQU-UHFFFAOYSA-N;

CAS number : 231277-92-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 231277-92-2 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : GSK572016; GW2016; GW572016;

Chemical formula : C29H26ClFN4O4S;

NSC code : 727989;

ChEBI ID : CHEBI:49603;

Codes from synonyms : 50458; CDR0000390335; CDR0000302459; 296;

PubMed : 12214266;

Details

Origin ID

C26653;

UMLS CUI

C1506770;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Lapatinib [MeSH Descriptor]
- Lapatinib (substance) [SNOMED CT concept]
- Product containing lapatinib (medicinal product) [SNOMED CT concept]
- lapatinib [International Nonproprietary Name]
- lapatinib [ATC Code]
- lapatinib [MeSH concept]
chemical_or_drug_affects_gene_product
- Receptor Tyrosine Kinase [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Receptor Tyrosine Kinase Inhibition [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Inhibition of Cell Proliferation [NCIt concept]
- Phosphorylation Inhibition [NCIt concept]
- Positive Regulation of Apoptosis [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_salt_form
- Lapatinib Ditosylate [NCIt concept]
has_target
- Epidermal Growth Factor Receptor [NCIt concept]
- Protein Kinase B [NCIt concept]
- Receptor Tyrosine-Protein Kinase erbB-2 [NCIt concept]
is_component_of_chemotherapy_regimen
- Anastrozole/Lapatinib Regimen [NCIt concept]
- Anastrozole/Lapatinib/Trastuzumab Regimen [NCIt concept]
- Exemestane/Lapatinib Regimen [NCIt concept]
- Exemestane/Lapatinib/Trastuzumab Regimen [NCIt concept]
- Lapatinib/Letrozole [NCIt concept]
- Lapatinib/Letrozole Regimen [NCIt concept]
- Lapatinib/Letrozole/Trastuzumab Regimen [NCIt concept]
- Lapatinib/Temozolomide Regimen [NCIt concept]
is_free_acid_or_base_form_of
- Lapatinib Ditosylate [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients